Nombre del producto:tert-butyl N-(piperidin-4-yl)carbamate

IUPAC Name:tert-butyl N-(piperidin-4-yl)carbamate

CAS:73874-95-0
Fórmula molecular:C10H20N2O2
Pureza:98%
Número de catálogo:CM105412
Peso molecular:200.28

Unidad de embalaje Stock disponible Precio($) Cantidad
CM105412-100g in stock ǵǤ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :73874-95-0
Fórmula molecular:C10H20N2O2
Punto de fusión:-
Código de sonrisas:O=C(OC(C)(C)C)NC1CCNCC1
Densidad:
Número de catálogo:CM105412
Peso molecular:200.28
Punto de ebullición:
Nº Mdl:MFCD00798171
Almacenamiento:Store at 2-8°C.

Category Infos

Piperidines
Piperidine is an azacycloalkane that is cyclohexane in which one of the carbons is replaced by a nitrogen. Although piperidine is a common organic compound, it is an immensely important class of compounds medicinally: the piperidine ring is the most common heterocyclic subunit among FDA approved drugs.
Piperidine,Piperidine Price
if you want to know the latest news about piperidine and piperidine price, please come to our website and get a quote for free.

Column Infos

Gepotidacin
GSK announces positive headline results from the EAGLE-1 Phase III trial for Gepotidacin in uncomplicated urogenital gonorrhea. Gonorrhoea is the second most common sexually transmitted infection due to the pathogen N. gonorrhoeae. Untreated urogenital gonorrhea can cause serious and permanent health problems, such as pelvic inflammatory disease and infertility.
Gepotidacin is an investigational, first-in-class inhibitor of bacterial topoisomerase. It has a distinct mechanism of action that inhibits bacterial DNA replication by selectively interacting with two key bacterial enzymes, DNA gyrase and topoisomerase IV. Gepotidacin confers activity against most strains of E. coli and S. saprophyticus, and N. gonorrhoeae, including target pathogens resistant to current antibiotics.
Paltusotine
Crinetics’ once-daily oral paltusotine achieved the primary and all secondary endpoints in the phase 3 PATHFNDR-2 study in acromegaly patients.
Acromegaly is a serious rare disease generally caused by a pituitary adenoma, a benign tumor in the pituitary that secretes growth hormone (GH). Excess GH secretion causes excess secretion of IGF-1 from the liver. Prolonged exposure to increased levels of IGF-1 and GH leads to progressive and serious systemic complications, often resulting in bone, joint, cardiovascular, metabolic, cerebrovascular, or respiratory disease. 
Paltusotine is the first oral, once-daily selectively-targeted somatostatin receptor type 2 (SST2) agonist and is currently in investigational Phase 3 studies for acromegaly and a Phase 2 study for carcinoid syndrome. 

Related Products